Rank #1145FATE

Fate Therapeutics, Inc.

$1.40

2.19% (Daily)

Market Cap

$161.49M

Revenue

$7.14M

Rank by MCap

#1145

Sector

Healthcare

Industry

Biotechnology

CEO

Dr. Bahram Valamehr M.B.A., Ph.D.

Headquarters

San Diego, CA

Employees

181

About Fate Therapeutics, Inc.

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus e...